RU97104665A - METHOD FOR OBESITY TREATMENT - Google Patents

METHOD FOR OBESITY TREATMENT

Info

Publication number
RU97104665A
RU97104665A RU97104665/14A RU97104665A RU97104665A RU 97104665 A RU97104665 A RU 97104665A RU 97104665/14 A RU97104665/14 A RU 97104665/14A RU 97104665 A RU97104665 A RU 97104665A RU 97104665 A RU97104665 A RU 97104665A
Authority
RU
Russia
Prior art keywords
isolipan
day
treatment
diet
days
Prior art date
Application number
RU97104665/14A
Other languages
Russian (ru)
Other versions
RU2147228C1 (en
Inventor
М.М. Гинзбург
Г.С. Козупица
Original Assignee
М.М. Гинзбург
Filing date
Publication date
Application filed by М.М. Гинзбург filed Critical М.М. Гинзбург
Priority to RU97104665A priority Critical patent/RU2147228C1/en
Priority claimed from RU97104665A external-priority patent/RU2147228C1/en
Publication of RU97104665A publication Critical patent/RU97104665A/en
Application granted granted Critical
Publication of RU2147228C1 publication Critical patent/RU2147228C1/en

Links

Claims (1)

Способ лечения ожирения, включающий диету и применение диетического регулятора изолипана, отличающийся тем, что диету проводят в импульсном режиме, путем чередования, разгрузочных дней, когда питание осуществляется с помощью белково-углеводной смеси "Доктор-слим" и изолипана в дозе 15 мг однократно во второй половине разгрузочного дня, и дней, когда пациент питается обычными продуктами с уменьшением суточного потребления жира до 35-40 г, что позволяет при хорошей переносимости лечения и отсутствии побочных эффектов изолипана достигать снижения избыточной массы тела в среднем на 12,2±2,72 кг за 12 недель лечения, а при сохранении навыков питания со сниженным до 35-40 г в день содержанием жира избежать нарастания массы тела и рецидивов ожирения после окончания курса лечения.A method of treating obesity, including a diet and the use of a dietary regulator of isolipan, characterized in that the diet is carried out in a pulsed manner, by alternating, fasting days, when the meal is carried out using the Doctor-Slim protein-carbohydrate mixture and isolipan in a dose of 15 mg once a day the second half of the fasting day, and the days when the patient eats conventional foods with a decrease in daily fat intake to 35-40 g, which allows for good tolerance of treatment and the absence of side effects of Isolipan to achieve lower eniya overweight by an average of 12,2 ± 2,72 kg for 12 weeks, and while maintaining the eating habits reduced to 35-40 grams per day of fat to avoid the increase of body weight and obesity relapse after treatment.
RU97104665A 1997-03-25 1997-03-25 Method of obesity treatment RU2147228C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU97104665A RU2147228C1 (en) 1997-03-25 1997-03-25 Method of obesity treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU97104665A RU2147228C1 (en) 1997-03-25 1997-03-25 Method of obesity treatment

Publications (2)

Publication Number Publication Date
RU97104665A true RU97104665A (en) 1999-04-20
RU2147228C1 RU2147228C1 (en) 2000-04-10

Family

ID=20191185

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97104665A RU2147228C1 (en) 1997-03-25 1997-03-25 Method of obesity treatment

Country Status (1)

Country Link
RU (1) RU2147228C1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002972A1 (en) 2013-07-01 2015-01-08 University Of Southern California Fasting condition as dietary treatment of diabetes
RU2570164C2 (en) * 2014-01-24 2015-12-10 Марина Владимировна Кочина Method for weight reduction and dietary product pack for implementing it
RU2599197C1 (en) * 2015-04-13 2016-10-10 Ольга Николаевна Кузнецова Method for weight reduction
US11000057B2 (en) * 2015-05-06 2021-05-11 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
WO2021126227A1 (en) 2019-12-20 2021-06-24 Vector Vitale Ip Llc Composition and method for the prevention and treatment of obesity

Similar Documents

Publication Publication Date Title
RU2141844C1 (en) Pharmaceutical compound
Astrup et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women
EP0637239B1 (en) Use of beta-hydroxy-beta-methylbutyric acid for promoting nitrogen retention in humans
EP0482715B1 (en) Nutritional composition
US5055460A (en) Method for weight loss
Kirkham et al. Dual action of naloxone on feeding revealed by behavioural analysis: separate effects on initiation and termination of eating
RU2000133303A (en) METHOD FOR LOSS WEIGHT IN DOGS
NZ508798A (en) Pet food composition comprising L-carnitine, and its use in the manufacture of pet food products for promoting weight loss and/or increasing lean body mass and/or enhancing the satiety and decreasing voluntary food intake in overweight dogs
JPH05503508A (en) How to reduce blood cholesterol using arginine
WO2005123108A2 (en) Advanced vitamins and protein based nutritional supplements
RU97104665A (en) METHOD FOR OBESITY TREATMENT
JPH03219838A (en) Feed for reducing amount of accumulated body fat
CA2067243A1 (en) Compositions and methods for weight reduction
US20020018787A1 (en) Methods and compositions for modulating immune response and for the treatment of inflammatory disease
JP4484254B2 (en) Amino acid composition
US20140024674A1 (en) Trpm5 inhibitors support body weight reduction without reducing food intake
JP2003335698A (en) Therapeutic or preventive composition for hyperuricemia
Petty et al. Previously unrecognized congenital progeroid disorder
CA2291811A1 (en) Zinc and linoleic acid containing food
US5627152A (en) Method for increasing bodyweight
GB2292522A (en) Multi-vitamin preparation for treatment of the immune system
JP3207326B2 (en) Environmental cleansing food
Labban The Implications of HIV/AIDS on the Nutritional Status and the MNT for Its Patients
RU2147239C1 (en) General tonic nonspecific immunomodulating agent
Chow et al. Ontogeny of adrenalectomy and depletion-induced sodium appetite